Clinical trial BAY 88-8223 / 17096
A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Bayer |
| EudraCT Identifier | 2014-002114-23 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02258451 |
| Inclusion criteria | *HER negative hormone receptor positive breast cancer* received at least one line of hormonal therapy in the metastatic setting*eligible for exemestane and everolimus * experienced no more than 2 skeletal related event (SRE) |
| Last update |